MA-ABIOMED
13.9.2022 14:03:40 CEST | Business Wire | Press release
Abiomed (Nasdaq: ABMD) will highlight how Impella heart pumps help heart teams achieve more complete high-risk revascularization and heart recovery in the catheterization lab and operating room at the Transcatheter Cardiovascular Therapeutics (TCT) 2022 Conference, held in Boston from September 16 to 19.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220913005521/en/
Impella 5.5 with SmartAssist delivers full cardiac support with maximum unloading, allowing the heart to rest and recover. (Graphic: Business Wire)
During the conference, physician-researchers will present clinical data demonstrating Impella leads to higher survival rates for cardiogenic shock patients and quality of life improvements for heart failure patients. Additional presentations and live cases will describe how Impella innovation and best practices have advanced safety and ease-of-use. Attendees can also receive hands-on Impella training and learn about future Impella technology.
Clinical Data Presentations:
Impella will be featured in presentations on topics that include a new analysis of data from the STEMI-DTU pilot randomized controlled trial and new data on cardiogenic shock and myocarditis outcomes from the J-PVAD registry in Japan. The J-PVAD registry is overseen by 10 Japanese professional societies, including the Japanese Circulation Society.
Abiomed’s preCARDIA technology to treat acute decompensated heart failure (ADHF) will be featured in two presentations that provide data showing preCARDIA reduces stressed blood volume and improves urine sodium excretion in ADHF patients.
Additionally, Abiomed will host two symposia with physician-researchers discussing the benefits of Impella as a therapy for patients in cardiogenic shock and Impella-supported high-risk PCI. They are:
- From Shock Spiral to Survival: Achieving Heart Recovery in Cardiogenic Shock – This in-person symposium takes place on Saturday, September 17, from 12:45–1:45 pm EDT in the TCT Presentation Theatre. Navin K. Kapur, MD, Tufts Medical Center, Boston; Katherine Kunkel, MD, Piedmont Heart Institute, Atlanta; Junya Ako, MD, Kitasato University Hospital, Tokyo; and Jay Giri, MD, MPH, Penn Medicine, Philadelphia, will present on best practices for Impella use to improve cardiogenic shock survival. A panel discussion will take place that will also include William O’Neill, MD and Mir Babar Basir, DO, from Henry Ford Hospital, Detroit.
- The CAD’s Out of the Bag: Achieving Heart Recovery in High-Risk Revascularization – This symposium is in-person and will be live streamed from the TCT World Connect Theatre on Sunday, September 18, from 12:30–1:30 pm EDT. Jonathan Hill, MD, Royal Brompton and Harefield Hospital, London; and Kate Kearney, MD, University of Washington, Seattle, will discuss clinical trials and best practices for Impella-supported high-risk PCI. Additionally, Navin K. Kapur, MD, Tufts Medical Center, Boston, will discuss ventricular unloading and what can be learned from the STEMI-DTU randomized controlled trial. A panel discussion will take place that will also include Gregg Stone, MD, Mount Sinai Health System, New York; Amir Kaki, MD, Ascension St. John Hospital, Detroit; and Cindy Grines, MD, Northside Hospital, Atlanta.
A detailed agenda for each symposium is available at this link on the TCT website.
Technology and Training:
Physicians attending the conference can receive hands-on Impella best practice training in the TCT Training Pavilion on topics such as access and closure, Impella RP with SmartAssist insertion and advanced Impella management. The esteemed faculty teaching these courses are Rajiv Tayal, MD, Valley Health System, Ridgewood, NJ; Robert Salazar, MD, Memorial Hermann, Houston; and Dan Burkhoff, MD, PhD, Cardiovascular Research Foundation. A detailed agenda for each training is available at this link on the TCT website.
Conference attendees are invited to visit the Abiomed booth, in the TCT Exhibit Hall. Abiomed’s booth will feature the latest Impella technology, including Impella 5.5 with SmartAssist and Impella RP with SmartAssist. Future pipeline technology will be available to preview, including Impella ECP, Impella RP Flex, Impella BTR and preCARDIA. Additionally, advanced Impella trainers will be available to answer questions about Impella’s new heparin-free purge, provide a hands-on experience with the Impella simulator and guide attendees through Abiomed’s new virtual reality training technology.
Live Daily Recap Program:
Abiomed’s TCT daily recap program will broadcast live from 6:00–6:30 pm EDT on Saturday, September 17 through Monday, September 19. The program will summarize the day’s news from TCT. It will be hosted by Abiomed’s chief medical officer, Chuck Simonton, MD, and Abiomed’s vice president for professional education and medical communication, Seth Bilazarian, MD. To watch live, log on to www.heartrecovery.com.
ABOUT IMPELLA HEART PUMPS
The Impella 2.5® and Impella CP® with SmartAssist® are U.S. FDA approved to treat certain advanced heart failure patients undergoing elective and urgent percutaneous coronary interventions (PCI), such as stenting or balloon angioplasty, to reopen blocked coronary arteries.
Impella 2.5, Impella CP®, Impella CP with SmartAssist, Impella 5.0®, Impella LD® and Impella 5.5® with SmartAssist® are U.S. FDA approved to treat heart attack or cardiomyopathy patients in cardiogenic shock and have the unique ability to enable native heart recovery, allowing patients to return home with their own heart.
Impella RP® and Impella RP® with SmartAssist are U.S. FDA approved to treat right heart failure or decompensation following left ventricular assist device implantation, myocardial infarction, heart transplant or open-heart surgery.
ABOUT ABIOMED
Based in Danvers, Massachusetts, USA, Abiomed, Inc., is a leading provider of medical technology that provides circulatory support and oxygenation. Our products are designed to enable the heart to rest by improving blood flow and/or provide sufficient oxygenation to those in respiratory failure. For additional information, please visit: http://www.abiomed.com.
FORWARD-LOOKING STATEMENTS
Any forward-looking statements are subject to risks and uncertainties such as those described in Abiomed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005521/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas:Sector-Leading Organic Revenue Growth of 6.5% in FY 202525.2.2026 07:30:00 CET | Press release
Strong margin improvement to 16.3% in FY 2025Positive growth outlook with continued margin expansion in 2026New EUR 200 million share buyback Bureau Veritas (BOURSE:BVI): 2025 key figures1 › Full-year revenue of EUR 6,466.4 million, up 6.5% organically (with 6.3% organic growth in Q4). At constant currency, the growth was up 7.3% year-on-year and up 3.6% on a reported basis, › Adjusted operating profit of EUR 1,052.9 million, up 5.7% versus EUR 996.2 million in FY 2024, representing an adjusted operating margin of 16.3%, up 32 basis points year-on-year and up 51 basis points at constant currency, › Operating profit of EUR 992.4 million, up 6.3% versus EUR 933.4 million in FY 2024, › Adjusted net profit of EUR 631.4 million, up 1.7% versus EUR 620.7 million in FY 2024, › Adjusted EPS stood at EUR 1.42 in 2025, with a 2.8% increase versus FY 2024 (EUR 1.38 per share) and up 9.2% at constant currency, › Attributable net profit of EUR 588.0 million, up 3.3% versus EUR 569.4 million in FY 2
Galderma Announces Triple Approval of New State-of-the-Art Restylane® Syringe in the EU, the U.S., and Canada, Reaffirming the Company’s Position at the Forefront of Injectable Aesthetics25.2.2026 07:00:00 CET | Press release
Regulatory authorities in the European Union (EU), the United States (U.S.), and Canada have approved a new state-of-the-art Restylane®syringe for use with a range of Restylane NASHA® lidocaine products in multiple indications in the face and in the hands1-3 Developed in collaboration with aesthetic practitioners, its innovative ergonomic design features a cushioned finger grip and thumb rest, to improve practitioner experience through better injection comfort and control, helping them deliver consistently premium results 4-7 The syringe’s carton packaging is the first in the industry to be made from 100% recyclable paper, and reaffirms Galderma’s commitment to sustainability and environmental responsibility 8 These approvals demonstrate Galderma’s strong heritage in Injectable Aesthetics, and its commitment to continuing to drive innovation in the field Galderma (SIX: GALD), today announced that regulatory authorities in the EU, the U.S., and Canada have approved a new state-of-the-ar
Azafaros Announces Publication of Preclinical Efficacy Data with Nizubaglustat in GM2 Gangliosidosis25.2.2026 07:00:00 CET | Press release
Preclinical proof-of-concept data in GM2 gangliosidosis demonstrated survival benefit, functional improvement and target engagementResults are published in the 7 January issue of the Journal of Inherited Metabolic DiseaseNizubaglustat is currently in Phase 3 registrational studies in GM1/GM2 gangliosidoses and Niemann-Pick type C disease (NPC) Azafaros, a company aiming to become a leader in lysosomal storage disorders (LSDs), focused on addressing especially neurological symptoms, today announced the publication of proof-of-concept preclinical data with its lead product, nizubaglustat, in GM2 gangliosidosis. The data, published in the 7 January issue of the Journal of Inherited Metabolic Disease in collaboration with the laboratory of Dr. Jagdeep Walia, Department of Pediatrics, Queen's University, Kingston, Canada, reinforce nizubaglustat’s potential to address unmet needs in rare LSDs and build on existing preclinical and clinical evidence. The preclinical study tested nizubaglustat
Verdict Expected Soon in Klarna’s $8.3 Billion Antitrust Lawsuit Against Google24.2.2026 19:09:00 CET | Press release
PriceRunner v. Google: Sweden’s Largest-Ever Civil Damages Claim Reaches Decision Stage; Klarna Provides Investor Update Klarna Group plc (NYSE: KLAR) announces that the Patent and Market Court of Sweden (Patent- och marknadsdomstolen) is expected to deliver its verdict on April 15, 2026 in the antitrust damages proceedings brought by Klarna’s subsidiary PriceRunner International AB against Google LLC and Google Ireland Limited. The trial, which ran from October 20 to December 19, 2025, concerned PriceRunner’s claim for approximately $8.3 billion in damages — the largest civil damages claim ever filed in a Swedish court. The Case The claim arises from Google’s abuse of dominance in online comparison shopping, as established by the European Commission in a binding 2017 decision and upheld without reservation by the Court of Justice of the European Union in September 2024. PriceRunner alleges that Google systematically demoted competing price comparison services in its search results whi
INRIX Announces New Generation of AI Traffic Products: Helping to Improve Safety, Reduce Congestion, and Enhance Mobility Operations24.2.2026 16:49:00 CET | Press release
New generative AI capabilities, enhanced incident detection, and expanded customer deployments mark a major evolution of the INRIX Traffic product family INRIX, a global leader in transportation data and analytics, today announced a major expansion of its Trafficfamily of products, delivering innovativeAI-driven capabilities to help transportation agencies and logistics organizations move from reactive traffic management to proactive, safety-focused and efficient operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260224267928/en/ INRIX introduces expanded automation, generative AI capabilities, enhanced incident detection, and continuous analytics. Over twenty years ago, INRIX commercialized the first system to use GPS data to create real-time traffic information. In 2019, INRIX launched AI Traffic – the world's first traffic platform to leverage deep learning models and AI to improve the quality and analysis globall
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom